carfilzomib Impurities
Daicel specializes in providing high-quality impurity standards for Carfilzomib, a second-generation proteasome inhibitor used in the treatment of relapsed or refractory multiple myeloma. With expertise in peptide synthesis and impurity characterization, Daicel ensures the production of highly purified impurity standards that are crucial for regulatory submissions, method validation, and quality control.
References
FAQ's
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.